BioLine RxBLRX +3.20%23 Quick Ratio is 1.43 as of Mar. 2026, which is 68% below its 10-year median of 4.41. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, BioLine Rx ranks worse than 73.73% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. BioLine Rx's quick ratio for the quarter that ended in Mar. 2026 was 1.43.
BioLine Rx has a quick ratio of 1.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioLine Rx's Quick Ratio or its related term are showing as below:
BLRX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.05 Med: 4.41 Max: 15.22
Current: 1.43
During the past 13 years, BioLine Rx's highest Quick Ratio was 15.22. The lowest was 1.05. And the median was 4.41.
BLRX's Quick Ratio is ranked worse than 73.73% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs BLRX: 1.43
BioLine Rx (NAS:BLRX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioLine Rx Quick Ratio Related Terms
BioLine Rx Quick Ratio Historical Data
* Premium members only.
The historical data trend for BioLine Rx's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioLine Rx's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioLine Rx's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLine Rx (BLRX) has a Quick Ratio of 1.43 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioLine Rx and its competitors. This is 68% below median its historical median of 4.41. Over the past decade, BioLine Rx's Quick Ratio has ranged from 1.05 to 15.22. According to the industry distribution chart, BioLine Rx ranks #1044 out of 1416 companies in the Biotechnology industry, placing it in the top 73.7%.
Is BioLine Rx's Quick Ratio too high?
BioLine Rx's current Quick Ratio of 1.43 is 68% below median its 10-year median of 4.41. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 15.22. The Biotechnology industry median Quick Ratio is 3.60. BioLine Rx's value of 1.43 is 60.3% below this industry median. Based on the distribution chart, BioLine Rx ranks #1044 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #1044 out of 1416 companies for Quick Ratio. This places BioLine Rx in the lower half of its industry. The industry median Quick Ratio is 3.60. BioLine Rx's value of 1.43 is 60.3% below this benchmark. Historically, BioLine Rx's own Quick Ratio has ranged from 1.05 to 15.22 over the past decade. While the company's 10-year median is 4.41 vs. the industry median of 3.60, BioLine Rx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current Quick Ratio of 1.43 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioLine Rx and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current Quick Ratio is 1.43, which is 68% below median its own 10-year median of 4.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current Quick Ratio of 1.43. The current Quick Ratio is 1.43, which is 68% below median its 10-year median of 4.41 and 60.3% below the Biotechnology industry median of 3.60. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioLine Rx (BLRX), the current Quick Ratio is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score
Get the complete analysis for BLRX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLRX has been successfully added to your 
